Thermo Fisher Scientific (TMO) EBT Margin (2009 - 2026)

Thermo Fisher Scientific has reported EBT Margin for 18 years, with the latest figure at 16.04% in Q2 2026.

• EBT Margin for Q2 2026 came in at 16.04%, up 30.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 16.48% (up 25.0% YoY), and the FY2025 annual result was 16.4%, down 1.0% from the prior year.
• EBT Margin improved to 16.04% in Q2 2026, from 15.76% in the prior quarter.
• Over five years, EBT Margin peaked at 21.49% in Q2 2022 and troughed at 12.73% in Q2 2023.
• A 5-year average of 16.17% and a median of 16.01% in 2023 frame the typical range for EBT Margin.
• The widest annual swing landed in 2023, when EBT Margin sank 877 bps; it then soared 336 bps in 2024.
• A 5-year view of EBT Margin shows it stood at 15.52% in 2022, then increased by 3 bps to 15.98% in 2023, then gained by 7 bps to 17.03% in 2024, then rose by 3 bps to 17.63% in 2025, then retreated by 9 bps to 16.04% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 16.04% in Q2 2026, 15.76% in Q1 2026, and 17.63% in Q4 2025.